ACE and hematoma: In this pooled cohort of 2.411 patients, 96 (20.7%) out of 464 patients on ACE inhibitors developed recurrent hematoma vs. 313 (16.1%) patients out of a total of 1.947 without prior ACE inhibitor treatment (OR 1.362, 95% CI 1.055 to 1.758; p = 0.018) (see Figure 3).